JP2010540556A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540556A5
JP2010540556A5 JP2010527140A JP2010527140A JP2010540556A5 JP 2010540556 A5 JP2010540556 A5 JP 2010540556A5 JP 2010527140 A JP2010527140 A JP 2010527140A JP 2010527140 A JP2010527140 A JP 2010527140A JP 2010540556 A5 JP2010540556 A5 JP 2010540556A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
compound according
pharmaceutical
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010527140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540556A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/077673 external-priority patent/WO2009042767A1/en
Publication of JP2010540556A publication Critical patent/JP2010540556A/ja
Publication of JP2010540556A5 publication Critical patent/JP2010540556A5/ja
Pending legal-status Critical Current

Links

JP2010527140A 2007-09-26 2008-09-25 アザシチジン類似体およびその使用 Pending JP2010540556A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26
PCT/US2008/077673 WO2009042767A1 (en) 2007-09-26 2008-09-25 Azacytidine analogues and uses thereof

Publications (2)

Publication Number Publication Date
JP2010540556A JP2010540556A (ja) 2010-12-24
JP2010540556A5 true JP2010540556A5 (enExample) 2011-08-11

Family

ID=40511851

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010527139A Pending JP2010540555A (ja) 2007-09-26 2008-09-25 アザシチジン類似体およびその使用
JP2010527140A Pending JP2010540556A (ja) 2007-09-26 2008-09-25 アザシチジン類似体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010527139A Pending JP2010540555A (ja) 2007-09-26 2008-09-25 アザシチジン類似体およびその使用

Country Status (15)

Country Link
US (2) US8158605B2 (enExample)
EP (2) EP2205073A4 (enExample)
JP (2) JP2010540555A (enExample)
KR (2) KR20100072230A (enExample)
CN (2) CN101877964A (enExample)
AU (2) AU2008304380A1 (enExample)
BR (2) BRPI0817269A2 (enExample)
CA (2) CA2700267A1 (enExample)
IL (1) IL204690A0 (enExample)
MX (2) MX2010003261A (enExample)
NZ (2) NZ583824A (enExample)
RU (1) RU2488591C2 (enExample)
UA (2) UA99836C2 (enExample)
WO (2) WO2009042767A1 (enExample)
ZA (1) ZA201001660B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
MX2010003261A (es) * 2007-09-26 2010-08-18 Sinai School Medicine Analogos de azacitidina y usos de los mismos.
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
WO2012142411A1 (en) * 2011-04-15 2012-10-18 Clavis Pharma Asa Systems and methods for detecting hent1 expression in hematological disorders
JP6162709B2 (ja) 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
CN104271159B (zh) 2012-02-24 2017-11-28 西格诺药品有限公司 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2016106050A1 (en) * 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
CN109789155B (zh) 2015-12-03 2025-02-07 免疫规划公司 含有地西他滨、5-氮杂胞苷和四氢尿苷的组合物以及其用途
SG11201906404RA (en) 2017-03-20 2019-08-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
US20210363170A1 (en) * 2018-04-19 2021-11-25 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
WO2022035852A1 (en) * 2020-08-10 2022-02-17 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (enExample) 1963-12-22
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) * 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4981613A (en) 1986-11-04 1991-01-01 Fuji Photo Film Co., Ltd. Laser light source
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
EP0526646B1 (en) * 1991-02-19 1997-04-23 Fujitsu Limited Semiconductor device having an isolation region enriched in oxygen and a fabrication process thereof
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
DK0599968T3 (da) 1991-08-14 2000-04-17 Procter & Gamble Pharma Oxazolidinonderivater, der er egnede som antiarytmi- og antifibrilleringsmidler
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9515279D0 (en) 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (en) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Novel group 4 transition metal compounds
KR19990036272A (ko) 1995-08-08 1999-05-25 사우코넨 주시 제이 재조합 ｃ-프로테나제와 이의 공정, 제조방법 및 이의 용도
EP0881878A4 (en) 1995-09-15 2004-08-04 Anadys Pharmaceuticals Inc ARYLHYDRAZONE DERIVATIVES AS AN ANTIBACTERIAL AGENT
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0914116B1 (en) 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
JPH10158192A (ja) * 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
KR100483256B1 (ko) * 1997-01-24 2005-04-15 콘파마 아에스 젬시타빈 유도체
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
ES2194320T3 (es) * 1997-06-03 2003-11-16 Itochu Techno Chem Inc Sustancias naturales antivirales o antitumorales y uso de las mismas.
WO1999026958A1 (en) 1997-11-25 1999-06-03 Protarga, Inc. Nucleoside analog compositions and uses thereof
AU2300699A (en) * 1998-02-17 1999-08-30 Ono Pharmaceutical Co. Ltd. Amidino derivatives and drugs containing the same as the active ingredient
WO2000076979A1 (de) 1999-06-09 2000-12-21 Bayer Aktiengesellschaft Pyridincarboxamide und ihre verwendung als pflanzenschutzmittel
JP4979866B2 (ja) 1999-09-08 2012-07-18 リガンド・ファーマシューティカルズ・インコーポレイテッド 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
TR200201023T2 (tr) 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
EP1448579A1 (de) 2001-11-21 2004-08-25 Heidelberg Pharma Holding GmbH Phospholipid-derivate von nucleosiden als antitumorale arzneimittel
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
AU2003278904A1 (en) * 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
JPWO2004101593A1 (ja) 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
US7244732B2 (en) 2003-06-20 2007-07-17 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20080033172A1 (en) 2003-12-19 2008-02-07 Koronis Pharmaceuticals, Incorporated Mutagenic Heterocycles
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
AU2005210039B2 (en) 2004-02-04 2010-09-02 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007035783A2 (en) * 2005-09-19 2007-03-29 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
MX2010003261A (es) 2007-09-26 2010-08-18 Sinai School Medicine Analogos de azacitidina y usos de los mismos.

Similar Documents

Publication Publication Date Title
JP2010540555A5 (enExample)
JP2008510770A5 (enExample)
CN113784970A (zh) Erk抑制剂及其应用
JP2009502743A5 (enExample)
RU2010116274A (ru) Аналоги азацитидина и их применение
JP2013518089A5 (enExample)
EP4473980A3 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
JP2005521713A5 (enExample)
JP2012153722A5 (enExample)
TWI462908B (zh) 用於治療增生性失調症的化合物
JP2016506916A5 (enExample)
JP2013520502A5 (enExample)
JP2020097577A5 (enExample)
JP2009529540A5 (enExample)
JP2020511467A5 (enExample)
JP2008535903A5 (enExample)
JP2011529054A5 (enExample)
JP2012506870A5 (enExample)
JP2008508303A5 (enExample)
JP2017530171A5 (enExample)
JP2014193925A5 (enExample)
JP2016501221A5 (enExample)
JP2013536227A5 (enExample)
JP2009536221A5 (enExample)
JP2014530818A5 (enExample)